Stem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative

Conference Recording   Oct 18, 2016

 
 
Gary Gintant

Abbvie

 
 
 
 
 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE